HK1057700A1 - Use of imidazoquinolinamines as adjuvants in dna vaccination - Google Patents
Use of imidazoquinolinamines as adjuvants in dna vaccinationInfo
- Publication number
- HK1057700A1 HK1057700A1 HK03108643.1A HK03108643A HK1057700A1 HK 1057700 A1 HK1057700 A1 HK 1057700A1 HK 03108643 A HK03108643 A HK 03108643A HK 1057700 A1 HK1057700 A1 HK 1057700A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- imidazoquinolinamines
- adjuvants
- dna vaccination
- vaccination
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0023008.6A GB0023008D0 (en) | 2000-09-20 | 2000-09-20 | Improvements in vaccination |
PCT/GB2001/004207 WO2002024225A1 (en) | 2000-09-20 | 2001-09-20 | Use of immidazoquinolinamines as adjuvants in dna vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1057700A1 true HK1057700A1 (en) | 2004-04-16 |
Family
ID=9899764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03108643.1A HK1057700A1 (en) | 2000-09-20 | 2003-11-26 | Use of imidazoquinolinamines as adjuvants in dna vaccination |
Country Status (25)
Country | Link |
---|---|
US (3) | US20040076633A1 (xx) |
EP (1) | EP1318835B1 (xx) |
JP (1) | JP2004509150A (xx) |
KR (1) | KR100876263B1 (xx) |
CN (1) | CN1197620C (xx) |
AR (1) | AR035586A1 (xx) |
AT (1) | ATE401097T1 (xx) |
AU (2) | AU2001287908B2 (xx) |
BR (1) | BR0113982A (xx) |
CA (1) | CA2422863A1 (xx) |
CZ (1) | CZ2003792A3 (xx) |
DE (1) | DE60134866D1 (xx) |
ES (1) | ES2309086T3 (xx) |
GB (1) | GB0023008D0 (xx) |
HK (1) | HK1057700A1 (xx) |
HU (1) | HUP0301180A3 (xx) |
IL (1) | IL154947A0 (xx) |
MX (1) | MXPA03002453A (xx) |
MY (1) | MY138978A (xx) |
NO (1) | NO20031274L (xx) |
NZ (1) | NZ524792A (xx) |
PL (1) | PL360895A1 (xx) |
TW (1) | TWI287453B (xx) |
WO (1) | WO2002024225A1 (xx) |
ZA (1) | ZA200302231B (xx) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP1733735B1 (en) | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
DE60325838D1 (de) * | 2002-03-19 | 2009-03-05 | Glaxo Group Ltd | Imidazoquinolinamine als adjuvantien für hiv dna vakzine |
PT1487485E (pt) * | 2002-03-19 | 2011-03-11 | Powderject Res Ltd | Adjuvantes de imidazoquinolina para vacinas de adn |
GB0206461D0 (en) * | 2002-03-19 | 2002-05-01 | Glaxo Group Ltd | Improvements in vaccination |
BR0313587A (pt) * | 2002-08-15 | 2006-06-13 | 3M Innovative Properties Co | composições imunoestimuladoras e métodos de estimulação de uma resposta imune |
CA2510375A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
BRPI0412902A (pt) * | 2003-08-12 | 2006-09-26 | 3M Innovative Properties Co | compostos contendo imidazo substituìdo por oxima |
US20050048072A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
JP2007503268A (ja) * | 2003-08-25 | 2007-02-22 | スリーエム イノベイティブ プロパティズ カンパニー | 免疫応答修飾化合物の送達 |
WO2005020999A1 (en) | 2003-08-27 | 2005-03-10 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
US20050054665A1 (en) * | 2003-09-05 | 2005-03-10 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
ES2544477T3 (es) | 2003-10-03 | 2015-08-31 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con alcoxi |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
CN1906193A (zh) | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | 肟取代的咪唑环化合物 |
CA2545825A1 (en) * | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
NZ547467A (en) | 2003-11-25 | 2010-06-25 | 3M Innovative Properties Co | Substituted imidazo ring system and methods |
WO2005066170A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
JP2007517044A (ja) * | 2003-12-30 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド |
AU2005228150A1 (en) * | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
WO2005123080A2 (en) * | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US7897609B2 (en) * | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
WO2006009826A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
WO2006065280A2 (en) * | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
DE102004049223A1 (de) * | 2004-10-08 | 2006-04-20 | Johannes-Gutenberg-Universität Mainz | Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung |
EP1804583A4 (en) * | 2004-10-08 | 2009-05-20 | 3M Innovative Properties Co | ADJUVANT FOR DNA VACCINE |
WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
US7943609B2 (en) * | 2004-12-30 | 2011-05-17 | 3M Innovative Proprerties Company | Chiral fused [1,2]imidazo[4,5-C] ring compounds |
WO2006083440A2 (en) | 2004-12-30 | 2006-08-10 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
ES2538498T3 (es) * | 2004-12-30 | 2015-06-22 | Meda Ab | Utilización de Imiquimod para el tratamiento de metástasis cutáneas provenientes de un tumor de cáncer de mama |
JP2008530022A (ja) | 2005-02-04 | 2008-08-07 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫反応調節物質を含む水性ゲル処方物 |
AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
US7943610B2 (en) | 2005-04-01 | 2011-05-17 | 3M Innovative Properties Company | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
JP2009507856A (ja) * | 2005-09-09 | 2009-02-26 | コーリー ファーマシューティカル グループ,インコーポレイテッド | N−{2−[4−アミノ−2−(エトキシメチル)−1H−イミダゾ[4,5−c]キノリン−1−イル]−1,1−ジメチルエチル}メタンスルホンアミドのアミドおよびカルバマート誘導体ならびに方法 |
ZA200803029B (en) * | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
US8088790B2 (en) | 2005-11-04 | 2012-01-03 | 3M Innovative Properties Company | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods |
US8951528B2 (en) | 2006-02-22 | 2015-02-10 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007106854A2 (en) * | 2006-03-15 | 2007-09-20 | Coley Pharmaceutical Group, Inc. | Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods |
US8088788B2 (en) | 2006-03-15 | 2012-01-03 | 3M Innovative Properties Company | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods |
JP2009534428A (ja) * | 2006-04-25 | 2009-09-24 | インターツェル・アクチェンゲゼルシャフト | Hcvワクチン接種 |
US20090060928A1 (en) * | 2006-05-26 | 2009-03-05 | Jean-Claude Bystryn | Topical Toll Like Receptor Ligands as Vaccine Adjuvants |
AU2007257423B8 (en) | 2006-05-31 | 2012-02-16 | The Regents Of The University Of California | Purine analogs |
EP2029169A2 (en) * | 2006-06-20 | 2009-03-04 | Transgene S.A. | Recombinant viral vaccine |
EP2032701B1 (en) | 2006-06-23 | 2013-11-27 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptides involved in cancer |
WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
CN100450484C (zh) * | 2006-10-11 | 2009-01-14 | 北京科信必成医药科技发展有限公司 | 一种咪喹莫特混悬溶液及其凝胶剂 |
EP2510946B1 (en) | 2007-02-07 | 2015-08-05 | The Regents of The University of California | Conjugates of synthetic tlr agonists and uses therefor |
ES2527412T3 (es) * | 2007-02-15 | 2015-01-23 | Mannkind Corporation | Método para aumentar la respuesta de los linfocitos T |
US8709445B2 (en) | 2007-07-31 | 2014-04-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists |
WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
EP2508190B1 (en) * | 2009-12-03 | 2021-06-02 | Aureo Co., Ltd. | Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages |
CN101850117B (zh) * | 2010-06-03 | 2012-05-30 | 国家兽用生物制品工程技术研究中心 | 一种复方免疫佐剂及疫苗 |
ES2617451T3 (es) | 2010-08-17 | 2017-06-19 | 3M Innovative Properties Company | Composiciones lipidadas de compuestos modificadores de la respuesta inmunitaria, formulaciones, y métodos |
CA2829105C (en) | 2011-03-31 | 2019-09-24 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
JP6460789B2 (ja) | 2011-06-03 | 2019-01-30 | スリーエム イノベイティブ プロパティズ カンパニー | ポリエチレングリコールセグメントを有するヘテロ2官能性リンカー及び該リンカーから調製された免疫反応調節複合体 |
US9107958B2 (en) | 2011-06-03 | 2015-08-18 | 3M Innovative Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
EP3533468A1 (en) | 2012-01-09 | 2019-09-04 | ADC Therapeutics SA | Method for treating breast cancer |
GB201310578D0 (en) | 2013-06-13 | 2013-07-31 | Univ Nottingham Trent | Electroactive actuators |
US9642895B2 (en) | 2013-08-12 | 2017-05-09 | 3M Innovative Properties Company | Peptides for enhancing transdermal delivery |
CN115778654A (zh) | 2015-10-12 | 2023-03-14 | 瑞弗罗医疗公司 | 具有突出的药物递送特征部的支架以及相关的系统和方法 |
EP3445761A1 (en) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
WO2018217897A1 (en) * | 2017-05-23 | 2018-11-29 | David Weiner | Compositions and method for inducing an immune response |
EP3681534A1 (en) | 2017-09-13 | 2020-07-22 | Sanofi Pasteur | Human cytomegalovirus immunogenic composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) * | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
CA2269754A1 (en) * | 1996-10-23 | 1998-04-30 | American Home Products Corporation | Dna vaccines for herpes simplex virus 1 and 2 |
GB9818627D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
-
2000
- 2000-09-20 GB GBGB0023008.6A patent/GB0023008D0/en not_active Ceased
-
2001
- 2001-09-20 HU HU0301180A patent/HUP0301180A3/hu unknown
- 2001-09-20 AU AU2001287908A patent/AU2001287908B2/en not_active Ceased
- 2001-09-20 WO PCT/GB2001/004207 patent/WO2002024225A1/en active IP Right Grant
- 2001-09-20 CA CA002422863A patent/CA2422863A1/en not_active Abandoned
- 2001-09-20 AT AT01967535T patent/ATE401097T1/de not_active IP Right Cessation
- 2001-09-20 TW TW090123505A patent/TWI287453B/zh not_active IP Right Cessation
- 2001-09-20 AU AU8790801A patent/AU8790801A/xx active Pending
- 2001-09-20 JP JP2002528295A patent/JP2004509150A/ja active Pending
- 2001-09-20 EP EP01967535A patent/EP1318835B1/en not_active Revoked
- 2001-09-20 IL IL15494701A patent/IL154947A0/xx unknown
- 2001-09-20 AR ARP010104453A patent/AR035586A1/es unknown
- 2001-09-20 CN CNB018186173A patent/CN1197620C/zh not_active Expired - Fee Related
- 2001-09-20 MY MYPI20014415A patent/MY138978A/en unknown
- 2001-09-20 KR KR1020037004041A patent/KR100876263B1/ko not_active IP Right Cessation
- 2001-09-20 CZ CZ2003792A patent/CZ2003792A3/cs unknown
- 2001-09-20 PL PL01360895A patent/PL360895A1/xx not_active Application Discontinuation
- 2001-09-20 BR BR0113982-7A patent/BR0113982A/pt not_active Application Discontinuation
- 2001-09-20 DE DE60134866T patent/DE60134866D1/de not_active Expired - Lifetime
- 2001-09-20 US US10/380,981 patent/US20040076633A1/en not_active Abandoned
- 2001-09-20 MX MXPA03002453A patent/MXPA03002453A/es active IP Right Grant
- 2001-09-20 ES ES01967535T patent/ES2309086T3/es not_active Expired - Lifetime
- 2001-09-20 NZ NZ524792A patent/NZ524792A/en not_active IP Right Cessation
-
2003
- 2003-03-19 NO NO20031274A patent/NO20031274L/no unknown
- 2003-03-20 ZA ZA200302231A patent/ZA200302231B/en unknown
- 2003-11-26 HK HK03108643.1A patent/HK1057700A1/xx not_active IP Right Cessation
-
2007
- 2007-06-19 US US11/764,814 patent/US20070248614A1/en not_active Abandoned
-
2010
- 2010-09-15 US US12/882,470 patent/US20110002953A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20110002953A1 (en) | 2011-01-06 |
PL360895A1 (en) | 2004-09-20 |
EP1318835B1 (en) | 2008-07-16 |
KR100876263B1 (ko) | 2008-12-26 |
EP1318835A1 (en) | 2003-06-18 |
CN1473051A (zh) | 2004-02-04 |
NZ524792A (en) | 2004-09-24 |
HUP0301180A2 (hu) | 2004-03-01 |
IL154947A0 (en) | 2003-10-31 |
US20070248614A1 (en) | 2007-10-25 |
JP2004509150A (ja) | 2004-03-25 |
HUP0301180A3 (en) | 2005-11-28 |
ZA200302231B (en) | 2004-05-05 |
AU2001287908B2 (en) | 2005-06-30 |
US20040076633A1 (en) | 2004-04-22 |
GB0023008D0 (en) | 2000-11-01 |
ATE401097T1 (de) | 2008-08-15 |
DE60134866D1 (de) | 2008-08-28 |
AR035586A1 (es) | 2004-06-16 |
CZ2003792A3 (cs) | 2004-12-15 |
WO2002024225A1 (en) | 2002-03-28 |
TWI287453B (en) | 2007-10-01 |
CN1197620C (zh) | 2005-04-20 |
MXPA03002453A (es) | 2003-06-19 |
NO20031274D0 (no) | 2003-03-19 |
NO20031274L (no) | 2003-05-19 |
BR0113982A (pt) | 2003-08-19 |
CA2422863A1 (en) | 2002-03-28 |
ES2309086T3 (es) | 2008-12-16 |
KR20040023566A (ko) | 2004-03-18 |
MY138978A (en) | 2009-08-28 |
AU8790801A (en) | 2002-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1057700A1 (en) | Use of imidazoquinolinamines as adjuvants in dna vaccination | |
HUP0204250A3 (en) | Use of hiv-protein or -polynucleotide for vaccine produce | |
GB0020953D0 (en) | Vaccine | |
HUP0301092A3 (en) | Vaccine | |
IL155072A0 (en) | Vaccine | |
AU1591402A (en) | Vaccine | |
HUP0302951A3 (en) | Purification of hbv antigens for use in vaccines | |
GB0014288D0 (en) | Vaccine | |
EP1335953A4 (en) | POLYNUCLEOTIDE VACCINE ADJUVANTS AND FORMULATIONS CONTAINING CATIONIC SURFACTANTS, METHODS OF USE THEREOF | |
GB0014845D0 (en) | Vaccine | |
GB0026334D0 (en) | Vaccine | |
GB0105606D0 (en) | Immunogens and vaccines and their preparation and use | |
GB0025694D0 (en) | Vaccine | |
GB0003082D0 (en) | Vaccine | |
GB0015722D0 (en) | Vaccine | |
GB0006693D0 (en) | Vaccine | |
GB0015935D0 (en) | Vaccine | |
GB0027644D0 (en) | Fish vaccine | |
GB0031218D0 (en) | Metgod of vaccine preparation | |
AUPR042100A0 (en) | Vaccines and methods of vaccination | |
GB0008029D0 (en) | New vaccine formulations | |
GB0016686D0 (en) | Novel vaccine | |
GB0025574D0 (en) | Vaccine | |
GB0022005D0 (en) | Vaccine | |
GB0020693D0 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130920 |